Global Insulin Biosimilars Market Growth, Share, Size, Trends and Forecast (2025 - 2031)

By Type;

Rapid-Acting Biosimilars, Long-Acting Biosimilars, and Premixed Biosimilars.

By Indication;

Type I Diabetes and Type II Diabetes.

By End User;

Hospitals, Ambulatory Surgical Centers, and Others.

By Geography;

North America, Europe, Asia Pacific, Middle East & Africa and Latin America - Report Timeline (2021 - 2031).
Report ID: Rn157808837 Published Date: April, 2025 Updated Date: May, 2025

Introduction

Global Insulin Biosimilars Market (USD Million), 2021 - 2031

In the year 2024, the Global Insulin Biosimilars Market was valued at USD 3,306.71 million. The size of this market is expected to increase to USD 4,778.37 million by the year 2031, while growing at a Compounded Annual Growth Rate (CAGR) of 5.4%.


Global Insulin Biosimilars Market Growth, Share, Size, Trends and Forecast

*Market size in USD million

CAGR 5.4 %


Study Period2025 - 2031
Base Year2024
CAGR (%)5.4 %
Market Size (2024)USD 3,306.71 Million
Market Size (2031)USD 4,778.37 Million
Market ConcentrationMedium
Report Pages348
3,306.71
2024
4,778.37
2031

Major Players

  • Sanofi S.A
  • Boehringer Ingelheim
  • Eli Lilly & Co
  • NOVO Nordisk A/S
  • Mylan N.V
  • Pfizer Inc
  • Sandoz
  • Fresenius Kabi

Market Concentration

Consolidated - Market dominated by 1 - 5 major players

Global Insulin Biosimilars Market

Fragmented - Highly competitive market without dominant players


The global insulin biosimilars market is experiencing robust growth, fueled by the rising incidence of diabetes and the increasing demand for affordable treatment options.This growth highlights the expanding role of biosimilars as cost-effective alternatives to traditional insulin therapies, offering patients more accessible solutions for diabetes management.

Technological Advancements

Technological progress has been a key factor in the growth of the insulin biosimilars market. Significant advancements in biotechnology, such as improvements in recombinant DNA technology and cell culture systems, have enhanced both the production efficiency and quality of these biologics. These innovations not only guarantee the safety and effectiveness of insulin biosimilars but also contribute to making them more cost-effective. As a result, insulin biosimilars are becoming increasingly accessible to a wider population of diabetic patients worldwide.

Future Outlook

The future of the insulin biosimilars market looks promising, with continued growth expected. The expiration of patents for original insulin products, along with rising healthcare costs and a global focus on affordable healthcare solutions, will drive the increasing demand for biosimilars. As the market matures, ongoing R&D efforts and strategic partnerships will play an essential role in advancing insulin.

  1. Introduction
    1. Research Objectives and Assumptions
    2. Research Methodology
    3. Abbreviations
  2. Market Definition & Study Scope
  3. Executive Summary
    1. Market Snapshot, By Type
    2. Market Snapshot, By Indication
    3. Market Snapshot, By End User
    4. Market Snapshot, By Region
  4. Global Insulin Biosimilars Market Dynamics
    1. Drivers, Restraints and Opportunities
      1. Drivers
        1. Cost-effectiveness of Biosimilars
        2. Patent Expiry of Biologic Insulins
        3. Growing Demand for Accessible Healthcare
        4. Government Initiatives to Promote Biosimilar Adoption
      2. Restraints
        1. Complex Manufacturing Processes
        2. Intellectual Property Rights Issues
        3. Concerns Regarding Safety and Efficacy
        4. Market Competition from Established Brands
      3. Opportunities
        1. Strategic Collaborations and Partnerships
        2. Growing Acceptance of Biosimilars among Healthcare Professionals
        3. Development of Novel Formulations and Delivery Systems
        4. Patient Education and Awareness Initiatives
    2. PEST Analysis
      1. Political Analysis
      2. Economic Analysis
      3. Social Analysis
      4. Technological Analysis
    3. Porter's Analysis
      1. Bargaining Power of Suppliers
      2. Bargaining Power of Buyers
      3. Threat of Substitutes
      4. Threat of New Entrants
      5. Competitive Rivalry
  5. Market Segmentation
    1. Global Insulin Biosimilars Market, By Type, 2021 - 2031 (USD Million)
      1. Rapid-Acting Biosimilars
      2. Long-Acting Biosimilars
      3. Premixed Biosimilars
    2. Global Insulin Biosimilars Market, By Indication, 2021 - 2031 (USD Million)
      1. Type I Diabetes
      2. Type II Diabetes
    3. Global Insulin Biosimilars Market, By End User, 2021 - 2031 (USD Million)
      1. Hospitals
      2. Ambulatory Surgical Centers
      3. Others
    4. Global Insulin Biosimilars Market, By Geography, 2021 - 2031 (USD Million)
      1. North America
        1. United States
        2. Canada
      2. Europe
        1. Germany
        2. United Kingdom
        3. France
        4. Italy
        5. Spain
        6. Nordic
        7. Benelux
        8. Rest of Europe
      3. Asia Pacific
        1. Japan
        2. China
        3. India
        4. Australia & New Zealand
        5. South Korea
        6. ASEAN (Association of South East Asian Countries)
        7. Rest of Asia Pacific
      4. Middle East & Africa
        1. GCC
        2. Israel
        3. South Africa
        4. Rest of Middle East & Africa
      5. Latin America
        1. Brazil
        2. Mexico
        3. Argentina
        4. Rest of Latin America
  6. Competitive Landscape
    1. Company Profiles
      1. Sanofi S.A
      2. Boehringer Ingelheim
      3. Eli Lilly & Co
      4. NOVO Nordisk A/S
      5. Mylan N.V
      6. Pfizer Inc
      7. Sandoz
      8. Fresenius Kabi
  7. Analyst Views
  8. Future Outlook of the Market